Anavex Life Sciences

AVXL

Biotechnology · Healthcare

Also trades as: 0HFR.L

Price

$3.24

+0.11 (+3.51%)

Market Cap

$300.3M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+22.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 69.8M (2021) → 85.3M (2025)

Winston Score History

The full picture

Anavex Life Sciences is a small biotechnology company focused on developing drugs to treat brain diseases. Its main drug candidate, blarcamesine (also called ANAVEX2-73), is being studied as a potential treatment for Alzheimer's disease, Parkinson's disease, and certain rare neurological conditions. The company does not yet sell any approved products and is still in the clinical trial stage.

Anavex makes no product revenue today — it funds its research through equity raises and grants while spending heavily on clinical trials. The company is headquartered in Vancouver, Canada, and conducts trials across North America, Europe, and Australia. Its pipeline is almost entirely dependent on blarcamesine, which means a failed or delayed trial result could severely damage the company's prospects. The key near-term driver is regulatory progress for blarcamesine in Alzheimer's, but the path to approval remains uncertain and the company continues to burn cash without a clear timeline to profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+55.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$38M/ year

↓ Declining (-10% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

3.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~4 years

$127M cash & investments

$127M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-31.7%

Weak — -31.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial